Penumbra, Inc. (NYSE:PEN) Director Bridget O’rourke Sells 50 Shares

Penumbra, Inc. (NYSE:PEN) Director Bridget O’rourke sold 50 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $271.21, for a total value of $13,560.50. Following the sale, the director now owns 5,523 shares in the company, valued at approximately $1,497,892.83. The trade was a 0.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bridget O’rourke also recently made the following trade(s):

• On Monday, March 3rd, Bridget O’rourke sold 50 shares of Penumbra stock. The shares were sold at an average price of $285.48, for a total value of $14,274.00.

Penumbra Stock Performance

Shares of Penumbra stock opened at $276.62 on Friday. The firm has a market capitalization of $10.70 billion, a P/E ratio of 813.60, a price-to-earnings-growth ratio of 2.83 and a beta of 0.56. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The business’s fifty day simple moving average is $275.47 and its 200 day simple moving average is $251.25. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.09. The company had revenue of $315.52 million during the quarter, compared to analyst estimates of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. As a group, analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PEN shares. Wells Fargo & Company boosted their target price on shares of Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Canaccord Genuity Group boosted their target price on Penumbra from $323.00 to $340.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Bank of America assumed coverage on Penumbra in a report on Friday, March 14th. They issued a “buy” rating and a $320.00 price target on the stock. Morgan Stanley boosted their price objective on Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a report on Wednesday, February 19th. Finally, Robert W. Baird lifted their price target on shares of Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a research report on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $293.93.

Hedge Funds Weigh In On Penumbra

Several institutional investors have recently bought and sold shares of PEN. Norges Bank bought a new stake in shares of Penumbra in the fourth quarter valued at $54,396,000. T. Rowe Price Investment Management Inc. lifted its holdings in Penumbra by 47.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 707,061 shares of the company’s stock valued at $167,913,000 after purchasing an additional 227,506 shares during the last quarter. GAMMA Investing LLC boosted its position in Penumbra by 42,409.9% during the first quarter. GAMMA Investing LLC now owns 189,594 shares of the company’s stock worth $50,699,000 after purchasing an additional 189,148 shares during the period. Baillie Gifford & Co. increased its stake in shares of Penumbra by 23.4% in the fourth quarter. Baillie Gifford & Co. now owns 730,233 shares of the company’s stock worth $173,416,000 after purchasing an additional 138,387 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of Penumbra in the fourth quarter valued at approximately $23,866,000. Hedge funds and other institutional investors own 88.88% of the company’s stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.